<DOC>
	<DOCNO>NCT01608061</DOCNO>
	<brief_summary>The primary objective feasibility study evaluate safety DBS-f patient mild Alzheimer 's disease assess device and/or therapy related adverse event . The secondary objective preliminarily estimate treatment effect size outcomes interest 12 month post-randomization . The objective involve formal test hypothesis .</brief_summary>
	<brief_title>ADvance DBS-f Patients With Mild Probable Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . 4585 year age ( inclusive ) 2 . Probable Alzheimer 's disease accord National Institute Aging Alzheimer 's disease Association criterion . 3 . Must meet certain criterion cognitive behavioral rating scale 4 . If female , subject postmenopausal surgically sterile willing use birth control method duration study . 5 . An available caregiver willing participate . 6 . Subject living home likely remain home study duration . 7 . The subject currently take stable dose cholinesterase inhibitor ( AChEI ) medication least 60 day 1 . Must meet certain criterion cognitive behavioral rating scale 2 . Current major psychiatric disorder schizophrenia , bipolar disorder major depressive disorder base psychiatric consult screen visit 3 . History head trauma 2 year prior sign consent participate study 4 . History brain tumor , subdural hematoma , clinically significant ( judgment investigator ) spaceoccupying lesion CT MRI 5 . Active psychiatric disorder 6 . Mental retardation 7 . Current alcohol substance abuse define Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) 8 . Contraindications PET scan ( e.g. , insulin dependent diabetes ) 9 . Contraindications MRI scanning , include implant metallic device ( e.g . nonMRIsafe cardiac pacemaker neurostimulator ; artificial joint metal pin ; surgical clip ; implant metal part ) , claustrophobia discomfort confine space . 10 . Abnormal lab result , opinion investigator and/or enrollment review committee , would preclude participation study . 11 . Abnormal cardiovascular neurovascular disorder , opinion investigator and/or enrollment review committee , would preclude participation study . 12 . Unstable dos medication prescribe treatment memory loss Alzheimer 's disease . 13 . Currently prescribe nonAD medication , opinion investigator and/or enrollment review committee , would preclude participation study . 14 . Is unable unwilling comply protocol followup requirement . 15 . Has life expectancy &lt; 1 year . 16 . Is actively enrol another concurrent clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Mild probable Alzheimer 's Disease</keyword>
</DOC>